Article
Oncology
Rita C. Acurcio, Sabina Pozzi, Barbara Carreira, Marta Pojo, Nuria Gomez-Cebrian, Sandra Casimiro, Adelaide Fernandes, Andreia Barateiro, Vitor Farricha, Joaquim Brito, Ana Paula Leandro, Jorge A. R. Salvador, Luis Graca, Leonor Puchades-Carrasco, Luis Costa, Ronit Satchi-Fainaro, Rita C. Guedes, Helena F. Florindo
Summary: This study identifies a new class of small molecule candidates that can regulate the PD-L1/PD-1 signaling pathway, promoting the infiltration of effector CD8 T cells in the tumor microenvironment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Medicine, Research & Experimental
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Summary: Immunotherapy and oncolytic virotherapy have revolutionized cancer treatment. The combination of monoclonal antibodies targeting PD-1/PD-L1 with oncolytic Ads has shown promising potential in improving clinical responses to immune checkpoint inhibitors.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Surgery
Seiichiro Inoue, Yuta Takeuchi, Yutaka Horiuchi, Takashi Murakami, Akio Odaka
Summary: Tumor-infiltrating lymphocytes (TILs) play a critical role in the antitumor reaction through immune checkpoint inhibition targeting PD-1 and PD-L1. This study confirms the importance of lymphocytes in the immune response induced by blocking PD-1/PD-L1 and suggests that promoting the infiltration of activated CD8+ TILs into tumors may be an effective treatment for neuroblastoma.
JOURNAL OF SURGICAL RESEARCH
(2023)
Article
Immunology
Yu Cui, Xinyue Han, Hongtao Liu, Qi Xie, Yaping Guan, Beibei Yin, Junjuan Xiao, Dongfeng Feng, Xuan Wang, Junwei Li, Jinghua Chen, Xiaolin Liu, Xingyu Li, Weiwei Nie, Lin Ma, Hairong Liu, Jing Liang, Yan Li, Baocheng Wang, Jun Wang
Summary: This study finds that cancer patients have higher levels of endogenous glucocorticoid (GC) compared to healthy individuals. High baseline endogenous GC levels in cancer patients are associated with reduced efficacy of immune checkpoint blockade therapy, disease progression, and shortened survival. In addition, high endogenous GC levels are correlated with decreased immune cell numbers, increased cytokine levels, and reduced tumor infiltrating immune cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Wenwen Yang, Caining Lei, Shaoming Song, Wutang Jing, Chuanwei Jin, Shiyi Gong, Hongwei Tian, Tiankang Guo
Summary: There has been a paradigm shift in cancer treatment with the emergence of immune checkpoint inhibitors, targeting PD-1 and PD-L1 pathways. The efficacy of these drugs may be related to PD-L1 expression and other emerging biomarkers. Customized medication models and predictive markers are becoming the new trend in malignant tumor immunotherapy.
CANCER CELL INTERNATIONAL
(2021)
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Review
Immunology
Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen
Summary: Immunotherapies have revolutionized cancer treatment, but recurrent ovarian cancer remains difficult to treat. Recurrent ovarian cancer is a cold tumor with limited response to immunotherapy. However, combining immunotherapy with other treatments may improve outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Jamal Majidpoor, Keywan Mortezaee
Summary: The interaction between PD-L1 and PD-1 is crucial for immune evasion in cancers, with PD-L1 positivity generally associated with higher responses to immune checkpoint inhibition (ICI) but also poor prognosis. Triple negative breast cancer (TNBC) is aggressive, but shows meaningful responses to ICI. Combining anti-PD-1/PD-L1 with immune modulatory drugs has shown significant clinical benefits.
CLINICAL IMMUNOLOGY
(2021)
Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Biotechnology & Applied Microbiology
Kanako Shinada, Shuji Murakami
Summary: Perioperative therapy for non-small cell lung cancer, particularly neoadjuvant PD-1/PD-L1 blockade therapy, has the potential to improve overall survival and contribute to a breakthrough in cancer immunotherapy. However, there are concerns about its long-term efficacy and the need for adequate biomarkers to monitor patient prognosis. This article provides an overview of recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discusses the challenges it faces in the future.
ONCOTARGETS AND THERAPY
(2023)
Review
Immunology
Quanqing Tang, Shihao Li, Gaozhen Huang, Hongwei Liu
Summary: Urothelial carcinoma (UC) is a common malignant tumor. Platinum-based chemotherapy has been the standard treatment for metastatic UC, but immune checkpoint inhibitors (ICIs) offer hope for patients unfit for platinum therapy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Dhananj ay Yadav, Minseok Kwak, Pallavi Singh Chauhan, Nidhi Puranik, Peter C. W. Lee, Jun-O Jin
Summary: Cancer is the second leading cause of death worldwide. Traditional approaches like surgery, chemotherapy, and radiotherapy have been commonly used for cancer treatment. Cancer immunotherapy, a novel therapeutic modality, boosts the immune responses of patients against malignancy. Recent advances in nanotechnology have facilitated the development of successful and efficient anticancer drug systems based on nanoparticles.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Si-Cong Ma, Xue Bai, Xue-Jun Guo, Li Liu, Lu-Shan Xiao, Yan Lin, Jia-Le Tan, Xiao-Ting Cai, Yu-Xiang Wen, Hu Ma, Q. John Fu, Meng-Xin Leng, Yan-Pei Zhang, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Jian-Guo Zhou, Zhong-Yi Dong
Summary: This study aims to explore the predictive and prognostic effects of organ-specific metastases in non-small cell lung cancer (NSCLC) patients and develop a scoring system (METscore) to guide the clinical practice of PD-(L)1 blockade. The results suggest that patients with different organ-specific metastases respond differently to immunotherapy, and the METscore can assess the efficacy of PD-(L)1 blockade.
Article
Oncology
Prachi Bhave, Lalit Pallan, Georgina V. Long, Alexander M. Menzies, Victoria Atkinson, Justine V. Cohen, Ryan J. Sullivan, Vanna Chiarion-Sileni, Marta Nyakas, Katharina Kahler, Axel Hauschild, Ruth Plummer, Claudia Trojaniello, Paolo A. Ascierto, Lisa Zimmer, Dirk Schadendorf, Clara Allayous, Celeste Lebbe, Andrea Maurichi, Mario Santinami, Severine Roy, Caroline Robert, Thierry Lesimple, Sapna Patel, Judith M. Versluis, Christian U. Blank, Adnan Khattak, Andre van der Westhuizen, Matteo S. Carlino, Mark Shackleton, Andrew Haydon
Summary: The study found that patients who relapse after adjuvant TT respond well to subsequent anti-PD-1 therapy, with outcomes similar to those seen when first-line anti-PD-1 therapy is used in stage IV melanoma.
BRITISH JOURNAL OF CANCER
(2021)
Review
Pharmacology & Pharmacy
Saiful Islam, Shudong Wang, Nikola Bowden, Jennifer Martin, Richard Head
Summary: Repurposing existing non-cancer drugs for cancer therapeutics is an attractive approach to expand clinical pipelines. Systematic identification of repurposing opportunities, such as through commercial drug databases or kinome profiling, can accelerate the advancement of drugs for clinical validation in cancer treatment. Identifying cancer-associated kinase inhibitors and targeting new kinases offer potential for more effective anti-cancer actions.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Oncology
Mathew Lozinski, Nikola A. Bowden, Moira C. Graves, Michael Fay, Paul A. Tooney
Summary: Glioblastoma, known for its aggressive and treatment resistant nature, is considered one of the most lethal cancers. The significance of DNA repair mechanisms in tumor formation, aggression and treatment resistance is discussed, suggesting that inhibiting DNA repair may be a potential strategy in treating glioblastoma.
Article
Pharmacology & Pharmacy
Vishal Navani, Moira C. Graves, Giovana Celli Marchett, Hiren Mandaliya, Nikola A. Bowden, Andre van der Westhuizen
Summary: The study found a positive relationship between exposure to pembrolizumab and progression-free survival (PFS) and overall survival (OS) in metastatic melanoma. TIM-3, along with the co-expression of CXCR6 and TIM-3 on circulating CD4(+) T cells, were identified as potential biomarkers of treatment failure.
PHARMACOLOGY RESEARCH & PERSPECTIVES
(2021)
Review
Oncology
Vishal Navani, Daniel Y. C. Heng
Summary: Over the past decade, the treatment landscape of metastatic renal cell carcinoma has rapidly evolved with the introduction of combination therapies targeting immune checkpoints and vascular endothelial growth factor receptor. These approaches have significantly improved outcomes for patients, leading to durable disease control and prolonged overall survival. Thoughtful study design is essential to accurately estimate outcomes and integrate novel approaches into the standard of care.
Review
Biochemistry & Molecular Biology
Craig Gedye, Vishal Navani
Summary: Cytotoxic chemotherapy and targeted therapies have limitations in treating advanced cancers due to cancer heterogeneity. However, reconceptualizing cancer therapy as an ecological problem and adopting adaptive therapy can optimize treatment outcomes by controlling the evolution of cancer and delaying treatment resistance development. This approach has the potential to significantly increase progression-free survival.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Oncology
Vishal Navani, J. Connor Wells, Devon J. Boyne, Winson Y. Cheung, Darren M. Brenner, Bradley A. McGregor, Chris Labaki, Andrew L. Schmidt, Rana R. McKay, Luis Meza, Sumanta K. Pal, Frede Donskov, Benoit Beuselinck, Maxwell Otiato, Lisa Ludwig, Thomas Powles, Bernadett E. Szabados, Toni K. Choueiri, Daniel Y. C. Heng
Summary: Limited data exists regarding the efficacy of cabozantinib following contemporary first line therapy options in advanced kidney cancer. A real world database analysis of 346 patients revealed clinically meaningful activity of second line cabozantinib after all evaluated contemporary first line therapies, including immune checkpoint blockade combination approaches.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Vishal Navani, Daniel E. Meyers, Yibing Ruan, Devon J. Boyne, Dylan E. O'Sullivan, Samantha Dolter, Heidi AI Grosjean, Igor Stukalin, Daniel Y. C. Heng, Don G. Morris, Darren R. Brenner, Randeep Sangha, Winson Y. Cheung, Aliyah Pabani
Summary: This cohort study developed and validated a prognostic scoring system for patients with NSCLC. It identified three baseline characteristics, including Eastern Oncology Cooperative Group performance status, neutrophil to lymphocyte ratio, and lactate dehydrogenase, as prognostic factors for survival outcomes in patients treated with single-agent ICI. This simple prognostic scoring tool can help discriminate survival outcomes in patients with advanced NSCLC.
CLINICAL LUNG CANCER
(2023)
Article
Medicine, General & Internal
Alexander S. Watson, Siddhartha Goutam, Igor Stukalin, Benjamin W. Ewanchuk, Michael Sander, Daniel E. Meyers, Aliyah Pabani, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng, Jose G. Monzon, Vishal Navani
Summary: This study examines the association between immune-related adverse events (irAEs) and survival in patients with metastatic melanoma, particularly those receiving combination immune checkpoint blockade (ICB).
Article
Oncology
Igor Stukalin, Vishal Navani, Mehul Gupta, Yibing Ruan, Devon J. Boyne, Dylan E. O'Sullivan, Daniel E. Meyers, Siddhartha Goutam, Michael Sander, Benjamin W. Ewanchuk, Darren R. Brenner, Aleksi Suo, Winson Y. Cheung, Daniel Y. C. Heng, Jose G. Monzon, Tina Cheng
Summary: This study developed a new prognostic model associated with overall survival in advanced melanoma patients treated with immune checkpoint inhibitors (ICI), focusing on clinically accessible parameters at the start of ICI therapy.
Review
Oncology
Sunil Samnani, Faraz Sachedina, Mehul Gupta, Edward Guo, Vishal Navani
Summary: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma. Recent advancements in combination therapies with anti-programmed death-1 (PD-1) have improved the prognosis for ccRCC patients. However, resistance to therapy and disease progression still occur. This analysis focuses on the study of resistance mechanisms and discusses potential novel approaches to overcome resistance in the context of clinical trials.
CANCER DRUG RESISTANCE
(2023)
Article
Oncology
Andre van der Westhuizen, Megan Lyle, Moira C. Graves, Xiaoqiang Zhu, Jason W. H. Wong, Kerrie Cornall, Shu Ren, Leanna Pugliese, Richard Levy, Adeeb Majid, Ricardo E. Vilain, Nikola A. Bowden
Summary: This study investigated the clinical and translational aspects of azacitidine and carboplatin priming followed by anti-PD-L1 immunotherapy in patients with ICB-resistant melanoma. The results showed that this priming approach can stabilize the disease and resensitize it to ICB, offering a new potential treatment for ICB-resistant melanoma.
CANCER RESEARCH COMMUNICATIONS
(2022)
Article
Endocrinology & Metabolism
Vishal Navani, James F. Lynam, Steven Smith, Christine J. O'Neill, Christopher W. Rowe
Summary: A 77-year-old man was diagnosed with concurrent metastatic prostatic adenocarcinoma and functioning androgen-secreting adrenocortical carcinoma. Histopathological analysis revealed scant foci of prostatic adenocarcinoma throughout the adrenocortical carcinoma specimen. Castration was achieved post adrenalectomy with a subsequent drop in prostate-specific antigen levels.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
(2021)
Meeting Abstract
Oncology
Vishal Navani, Moira C. Graves, Giovana Celli Marchett, Hiren Mandaliya, Nikola A. Bowden, Andre Van Der Westhuizen
Article
Medicine, General & Internal
Avraham Travers, Kim Adler, Gillian Blanchard, Tony Bonaventura, Julie Charlton, Fiona Day, Laura Healey, Sang Kim, Janine Lombard, Girish Mallesara, Hiren Mandaliya, Vishal Navani, Ina Nordman, Robin Paterson, Louise Plowman, Gaik Tin Quah, Michael Scalley, Prajwol Shrestha, Bharti Tailor, Andre van der Westhuizen, Betty Zhang, Craig Gedye, James Lynam
Summary: The impact of COVID-19 on medical oncology care in Australia included fewer hospital admissions, increased telephone consultations, and decreased clinical trial activity. Despite these changes, the continuum of care was largely maintained during the pandemic.
INTERNAL MEDICINE JOURNAL
(2021)
